The oncolytic virus therapy market size has grown exponentially in recent years. It will grow from $0.15 billion in 2023 to $0.19 billion in 2024 at a compound annual growth rate (CAGR) of 26.2%. Historical growth stemmed from enhanced genetic engineering methods, heightened comprehension of the tumor microenvironment, successful clinical outcomes, regulatory endorsements, and the prominence of immunotherapy in cancer care, alongside progress in gene delivery systems.
The oncolytic virus therapy market size is expected to see exponential growth in the next few years. It will grow to $0.44 billion in 2028 at a compound annual growth rate (CAGR) of 23.9%. The anticipated growth in the upcoming period is expected due to the broadening of oncolytic virus platforms, the integration of combination therapies with immune checkpoint inhibitors, personalized medicine approaches, the widening landscape of clinical trials, and increased regulatory support and guidelines. Significant trends projected include technological advancements in delivery systems, progress in synthetic biology, collaborations and partnerships within the biopharmaceutical sector, advancements in virology and immunology, and a focused approach on pediatric oncology.
The escalating prevalence of cancer cases stands poised to drive the growth of the oncolytic virus therapy market. Cancer, a collective term for diseases characterized by uncontrolled cell growth, is a significant global health concern. Oncolytic virus therapy emerges as a promising approach, capable of selectively targeting and eliminating cancer cells while simultaneously triggering an immune response against tumors, providing a dual mechanism for effective cancer treatment. Notably, in January 2023, the American Cancer Society Inc. projected 609,820 cancer deaths and 1,958,310 new cancer cases in the United States for 2022. This stark reality underscores the urgent need for innovative therapeutic approaches, such as oncolytic virus therapy, to address the growing prevalence of cancer cases.
The oncolytic virus therapy market is expected to experience growth propelled by the increasing number of ongoing clinical trials. Clinical trials, essential research studies involving human participants, serve to assess the safety and efficacy of new medical treatments, interventions, or diagnostic procedures. The surge in clinical trials utilizing oncolytic virus therapy underscores the therapeutic potential of this approach, given its ability to selectively target cancer cells while sparing healthy tissue. As of October 2023, ClinicalTrials.gov reported a significant increase in registered studies, rising from 437,523 in 2022 to 468,457 across all 50 states of the United States and 221 countries. Notably, 143,613 studies (31% of the total) are registered in the U.S., with 251,159 studies (54% of the total) registered in non-U.S. locations. This proliferation of clinical trials signifies the growing interest and investment in oncolytic virus therapy as a promising avenue for cancer treatment, contributing to the market's expansion.
Product innovations emerge as a central trend gaining momentum, with major companies strategically focusing on the introduction of groundbreaking products to fortify their market standing. A notable example is Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company, which launched DELYTACT in Japan in November 2021. DELYTACT represents a significant milestone as the first oncolytic virus approved for primary brain cancer globally, featuring a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1). This innovative therapy operates by selectively replicating and eliminating tumor cells while sparing normal tissues, showcasing the transformative potential of oncolytic virus therapy in cancer treatment.
Strategic partnerships play a pivotal role in advancing comprehensive cancer treatments within the oncolytic virus therapy industry. RenovoRx Inc., a US-based clinical-stage biopharmaceutical company, and Imugene Ltd., an Australia-based clinical-stage immuno-oncology company, forged a strategic research collaboration in July 2023. The aim of this partnership is to optimize the delivery of Imugene’s oncolytic virus therapy leveraging RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform. Additionally, the collaboration seeks to explore the administration of Imugene’s CF33 oncolytic virus technology using RenovoRx’s TAMP therapy platform, with a specific focus on treating challenging-to-access tumors. This strategic alliance exemplifies the industry's commitment to collaborative efforts, driving advancements in oncolytic virus therapy for enhanced cancer treatment outcomes.
In April 2022, Recipharm AB, a pharmaceutical company based in Sweden, completed the acquisition of Vibalogics for an undisclosed sum. This strategic move enabled Recipharm AB to enhance its global presence significantly by integrating a comprehensive end-to-end portfolio encompassing development capabilities, GMP drug substance and drug product manufacturing, sterile fill & finish services, as well as analytical and quality control testing. Vibalogics, a German biotechnology firm and a Contract Development and Manufacturing Organization (CDMO), specializes in manufacturing oncolytic viruses, viral vaccines, and gene therapies.
Major companies operating in the oncolytic virus therapy market report are Pfizer Inc., Johnson & Johnson, Sorrento Therapeutics Inc., AbbVie Inc., AstraZeneca plc, Amgen Inc., Boehringer Ingelheim Group, Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, Eurofins Scientific SE, Recipharm AB, Kissei Pharmaceutical Co. Ltd., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Adze Biotechnology, Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Circio Holding ASA, Lokon Pharma AB, Provectus Biopharmaceuticals Inc., Vibalogics, SillaJen Inc.
North America was the largest region in the oncolytic virus therapy market in 2023, and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oncolytic virus therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The key categories of oncolytic virus therapy include HSV-based oncolytic virus therapy, adenovirus-based oncolytic virus therapy, reovirus, poxviruses, Newcastle disease virus (NDV), among others. HSV-based oncolytic virus therapy employs the herpes simplex virus (HSV) as the foundational component for treatment. Various virus types encompass genetically modified oncolytic viruses as well as oncolytic wild-type viruses. These therapies find application across different cancer types such as breast cancer, lung cancer, prostate cancer, melanoma, brain tumors, and blood cancer. They are utilized by healthcare institutions including hospitals, specialized clinics, and cancer research institutes.
The oncolytic virus therapy market research report is one of a series of new reports that provides oncolytic virus therapy market statistics, including oncolytic virus therapy industry global market size, regional shares, competitors with an oncolytic virus therapy market share, detailed oncolytic virus therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the oncolytic virus therapy industry. This oncolytic virus therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The oncolytic virus therapy market includes revenues earned by entities by providing seneca valley virus (SVV), semliki forest virus (SFV), vesicular stomatitis virus (VSV), and sindbis virus (SBV). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The oncolytic virus therapy market size is expected to see exponential growth in the next few years. It will grow to $0.44 billion in 2028 at a compound annual growth rate (CAGR) of 23.9%. The anticipated growth in the upcoming period is expected due to the broadening of oncolytic virus platforms, the integration of combination therapies with immune checkpoint inhibitors, personalized medicine approaches, the widening landscape of clinical trials, and increased regulatory support and guidelines. Significant trends projected include technological advancements in delivery systems, progress in synthetic biology, collaborations and partnerships within the biopharmaceutical sector, advancements in virology and immunology, and a focused approach on pediatric oncology.
The escalating prevalence of cancer cases stands poised to drive the growth of the oncolytic virus therapy market. Cancer, a collective term for diseases characterized by uncontrolled cell growth, is a significant global health concern. Oncolytic virus therapy emerges as a promising approach, capable of selectively targeting and eliminating cancer cells while simultaneously triggering an immune response against tumors, providing a dual mechanism for effective cancer treatment. Notably, in January 2023, the American Cancer Society Inc. projected 609,820 cancer deaths and 1,958,310 new cancer cases in the United States for 2022. This stark reality underscores the urgent need for innovative therapeutic approaches, such as oncolytic virus therapy, to address the growing prevalence of cancer cases.
The oncolytic virus therapy market is expected to experience growth propelled by the increasing number of ongoing clinical trials. Clinical trials, essential research studies involving human participants, serve to assess the safety and efficacy of new medical treatments, interventions, or diagnostic procedures. The surge in clinical trials utilizing oncolytic virus therapy underscores the therapeutic potential of this approach, given its ability to selectively target cancer cells while sparing healthy tissue. As of October 2023, ClinicalTrials.gov reported a significant increase in registered studies, rising from 437,523 in 2022 to 468,457 across all 50 states of the United States and 221 countries. Notably, 143,613 studies (31% of the total) are registered in the U.S., with 251,159 studies (54% of the total) registered in non-U.S. locations. This proliferation of clinical trials signifies the growing interest and investment in oncolytic virus therapy as a promising avenue for cancer treatment, contributing to the market's expansion.
Product innovations emerge as a central trend gaining momentum, with major companies strategically focusing on the introduction of groundbreaking products to fortify their market standing. A notable example is Daiichi Sankyo Company Limited, a Japan-based pharmaceutical company, which launched DELYTACT in Japan in November 2021. DELYTACT represents a significant milestone as the first oncolytic virus approved for primary brain cancer globally, featuring a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1). This innovative therapy operates by selectively replicating and eliminating tumor cells while sparing normal tissues, showcasing the transformative potential of oncolytic virus therapy in cancer treatment.
Strategic partnerships play a pivotal role in advancing comprehensive cancer treatments within the oncolytic virus therapy industry. RenovoRx Inc., a US-based clinical-stage biopharmaceutical company, and Imugene Ltd., an Australia-based clinical-stage immuno-oncology company, forged a strategic research collaboration in July 2023. The aim of this partnership is to optimize the delivery of Imugene’s oncolytic virus therapy leveraging RenovoRx’s TAMP (Trans-Arterial Micro-Perfusion) therapy platform. Additionally, the collaboration seeks to explore the administration of Imugene’s CF33 oncolytic virus technology using RenovoRx’s TAMP therapy platform, with a specific focus on treating challenging-to-access tumors. This strategic alliance exemplifies the industry's commitment to collaborative efforts, driving advancements in oncolytic virus therapy for enhanced cancer treatment outcomes.
In April 2022, Recipharm AB, a pharmaceutical company based in Sweden, completed the acquisition of Vibalogics for an undisclosed sum. This strategic move enabled Recipharm AB to enhance its global presence significantly by integrating a comprehensive end-to-end portfolio encompassing development capabilities, GMP drug substance and drug product manufacturing, sterile fill & finish services, as well as analytical and quality control testing. Vibalogics, a German biotechnology firm and a Contract Development and Manufacturing Organization (CDMO), specializes in manufacturing oncolytic viruses, viral vaccines, and gene therapies.
Major companies operating in the oncolytic virus therapy market report are Pfizer Inc., Johnson & Johnson, Sorrento Therapeutics Inc., AbbVie Inc., AstraZeneca plc, Amgen Inc., Boehringer Ingelheim Group, Regeneron Pharmaceuticals, Daiichi Sankyo Company Limited, Eurofins Scientific SE, Recipharm AB, Kissei Pharmaceutical Co. Ltd., Takara Bio Inc., Oncorus Inc., Replimune Inc., Vyriad Inc., Genelux Corporation, Oncolys BioPharma Inc., Adze Biotechnology, Oncolytics Biotech Inc., TILT Biotherapeutics Ltd., Transgene SA, Circio Holding ASA, Lokon Pharma AB, Provectus Biopharmaceuticals Inc., Vibalogics, SillaJen Inc.
North America was the largest region in the oncolytic virus therapy market in 2023, and is expected to be the fastest-growing region in the forecast period. The regions covered in the oncolytic virus therapy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the oncolytic virus therapy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.
The key categories of oncolytic virus therapy include HSV-based oncolytic virus therapy, adenovirus-based oncolytic virus therapy, reovirus, poxviruses, Newcastle disease virus (NDV), among others. HSV-based oncolytic virus therapy employs the herpes simplex virus (HSV) as the foundational component for treatment. Various virus types encompass genetically modified oncolytic viruses as well as oncolytic wild-type viruses. These therapies find application across different cancer types such as breast cancer, lung cancer, prostate cancer, melanoma, brain tumors, and blood cancer. They are utilized by healthcare institutions including hospitals, specialized clinics, and cancer research institutes.
The oncolytic virus therapy market research report is one of a series of new reports that provides oncolytic virus therapy market statistics, including oncolytic virus therapy industry global market size, regional shares, competitors with an oncolytic virus therapy market share, detailed oncolytic virus therapy market segments, market trends, and opportunities, and any further data you may need to thrive in the oncolytic virus therapy industry. This oncolytic virus therapy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The oncolytic virus therapy market includes revenues earned by entities by providing seneca valley virus (SVV), semliki forest virus (SFV), vesicular stomatitis virus (VSV), and sindbis virus (SBV). The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Oncolytic Virus Therapy Market Characteristics3. Oncolytic Virus Therapy Market Trends and Strategies32. Global Oncolytic Virus Therapy Market Competitive Benchmarking33. Global Oncolytic Virus Therapy Market Competitive Dashboard34. Key Mergers and Acquisitions in the Oncolytic Virus Therapy Market
4. Oncolytic Virus Therapy Market - Macro Economic Scenario
5. Global Oncolytic Virus Therapy Market Size and Growth
6. Oncolytic Virus Therapy Market Segmentation
7. Oncolytic Virus Therapy Market Regional and Country Analysis
8. Asia-Pacific Oncolytic Virus Therapy Market
9. China Oncolytic Virus Therapy Market
10. India Oncolytic Virus Therapy Market
11. Japan Oncolytic Virus Therapy Market
12. Australia Oncolytic Virus Therapy Market
13. Indonesia Oncolytic Virus Therapy Market
14. South Korea Oncolytic Virus Therapy Market
15. Western Europe Oncolytic Virus Therapy Market
16. UK Oncolytic Virus Therapy Market
17. Germany Oncolytic Virus Therapy Market
18. France Oncolytic Virus Therapy Market
19. Italy Oncolytic Virus Therapy Market
20. Spain Oncolytic Virus Therapy Market
21. Eastern Europe Oncolytic Virus Therapy Market
22. Russia Oncolytic Virus Therapy Market
23. North America Oncolytic Virus Therapy Market
24. USA Oncolytic Virus Therapy Market
25. Canada Oncolytic Virus Therapy Market
26. South America Oncolytic Virus Therapy Market
27. Brazil Oncolytic Virus Therapy Market
28. Middle East Oncolytic Virus Therapy Market
29. Africa Oncolytic Virus Therapy Market
30. Oncolytic Virus Therapy Market Competitive Landscape and Company Profiles
31. Oncolytic Virus Therapy Market Other Major and Innovative Companies
35. Oncolytic Virus Therapy Market Future Outlook and Potential Analysis
36. Appendix
Executive Summary
Oncolytic Virus Therapy Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on oncolytic virus therapy market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
- Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for oncolytic virus therapy? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
- The impact of higher inflation in many countries and the resulting spike in interest rates.
- The continued but declining impact of COVID-19 on supply chains and consumption patterns.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Report Scope
Markets Covered:1) By Therapy Type: HSV-based Oncolytic Virus Therapy; Adenovirus-based Oncolytic Virus Therapy; Reovirus; Poxviruses; NDV (Newcastle Disease Virus); Other Therapy Types
2) By Virus Type: Genetically Engineered Oncolytic Viruses; Oncolytic Wild-Type Viruses
3) By Application: Breast Cancer; Lung Cancer; Prostate Cancer; Melanoma; Brain Tumor; Blood Cancer
4) By End-user: Hospitals; Specialty Clinics; Cancer Research Institutes
Key Companies Mentioned: Pfizer Inc.; Johnson & Johnson; Sorrento Therapeutics Inc.; AbbVie Inc.; AstraZeneca plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes
Delivery Format: PDF, Word and Excel Data Dashboard
Companies Mentioned
- Pfizer Inc.
- Johnson & Johnson
- Sorrento Therapeutics Inc.
- AbbVie Inc.
- AstraZeneca plc
- Amgen Inc.
- Boehringer Ingelheim Group
- Regeneron Pharmaceuticals
- Daiichi Sankyo Company Limited
- Eurofins Scientific SE
- Recipharm AB
- Kissei Pharmaceutical Co. Ltd.
- Takara Bio Inc.
- Oncorus Inc.
- Replimune Inc.
- Vyriad Inc.
- Genelux Corporation
- Oncolys BioPharma Inc.
- Adze Biotechnology
- Oncolytics Biotech Inc.
- TILT Biotherapeutics Ltd.
- Transgene SA
- Circio Holding ASA
- Lokon Pharma AB
- Provectus Biopharmaceuticals Inc.
- Vibalogics
- SillaJen Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 175 |
| Published | February 2024 |
| Forecast Period | 2024 - 2028 |
| Estimated Market Value ( USD | $ 0.19 Billion |
| Forecasted Market Value ( USD | $ 0.44 Billion |
| Compound Annual Growth Rate | 23.9% |
| Regions Covered | Global |
| No. of Companies Mentioned | 27 |
